NOS1 and persistent truncus arteriosus: The studies with an NOS inhibitor, L-NAME, showed that co-administration of this compound enhanced capillary rarefaction and inhibited improvement of cardiac dysfunction in the TAC + EMPA group, indicating that the eNOS/NO axis is crucial for the cardioprotective effects of EMPA.